News Briefs

BlossomHill Therapeutics rallies $71m Series A

BlossomHill Therapeutics Inc, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71 million in Series A financing.

Iris Dorbian

4 March 2021

BlossomHill Therapeutics Inc, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71 million in Series A financing. The investors included Cormorant Asset Management, Hercules BioVentures Partners LLC, OrbiMed Advisors and Vivo Capital.

Source: Press Release

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Nearly there!

Share this:

Register now

Login

Sign in to your account

Nearly there!

We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there.